


Capability Statement

Florida Analytical Imaging Solutions' unique image analytics derive actionable results from intractably amorphous biological images, whether gross, such as CT, X-ray, MRI, or microscopic data. This is made possible by FAIS automated image analysis for segregation, isolation, and analysis of sub-cellular or gross structures with 95%-99% accuracy. For Covid-19 diagnostics and prognosis, FAIS is able to process lung image data sets to correlate physical disease attributes with identification of disease state and preferred treatment options. FAIS seeks access to Covid-19 lung image databases, through collaboration with hospitals, insurers, or others, to enable derivation of this important information. FAIS image analytics have been applied successfully to tumor detection and prognosis.




The separated lung masks in different colors fit in the two lung areas very well

CAGE: 6USA8 | DUNS: 078746630 | Email: contact@flaimaging.com


Core Competencies

FAIS Image Analytics

We've patented a method and system for selecting a region of interest (ROI) in a tissue or groups of cells, in which all steps are automatic. In various exemplary embodiments, the method and system can be applied to centrosome analysis with excellent accuracy and precision. Centrosome analysis is an important tool in very early cancer diagnosis and cancer prognosis. Automatic region of interest selection in centrosome analysis. **USA Patent No: 10818015, October, 2020**




Patented method for selecting a region of interest (ROI)



Fully-automatic ROI selection separated cells and their centrosomes

Covid-19 Diagnostics & Prognosis


We are able to process lung image data sets to correlate physical disease attributes with identification of disease state and preferred treatment options. FAIS image analytics have been applied successfully to lung tumor detection, lung cancer diagnosis and prognosis, and mammogram tumor detection.



Automatically selected ROI (Region of Interest)

Cancer Diagnosis: Biomarkers

FAIS has significant additional capability in assessment of cancer treatment efficacy resulting from the combination of FAIS imaging analytics with our particular expertise in the analysis of centrosomes, sub-nuclear cell components involved in cell mitosis, aberrations in which are critically linked to cancer and cancer progression.



Mammogram with tumor (far right image after cleaning/enhancement/segmentation)

Differentiators

The patented FAIS Centrosome Image Analysis software has proven effective for use in medical image analysis and has seamlessly integrated with health records to improve efficiency. Our research pioneers new visions for cancer treatments. One valuable application of our technology within the biomedical imaging field is our Centrosome Image System that discriminates cancer from normal cells in cell-based and histology specimens. The revolutionary Centrosome Image System can be used for the early diagnosis of cancer, prognosis of cancers' progression and in evaluation of cancer treatment response.

Company Snapshot

Gov. Business POC's: Tatyana Zhukov | Dansheng Song | Victoria Link

E-Mail: contact@flaimaging.com

Address: 1882 Pine Ridge Way West, Unit A-2
Palm Harbor, FL 34684-2140

Work Area: Nationwide

Socio-Economic:

- Woman-Owned Business
- Woman-Owned Small Business

Primary NAICS & PSC Codes:

- **541714** - R&D in Biotechnology (except Nanobiotechnology)
- **541511** - Custom Computer Programming Services
- **621512** - Diagnostic Imaging Centers
- **AN11** - R&D: Biomedical-Basic Research

Past Performance

- Lung Cancer Cell Selections for Flow Optical tomography, NIH grant, 2002-2005.
- The Biomarker Development Laboratory at Moffitt (BeDLAM), 1999-2006.
- Luminescence Characterization of Quantum Dots Conjugated with Biomarkers for Early Cancer Detection. USA Patent No: 7655479, Feb. 2010.
- Computer-Aided Pathological Diagnosis (CAPD). USA Patent No: 8077958, Dec. 2011.
- Discovery of Distinct Protein Profiling Specific for Lung Tumors and Premalignant Lung Lesions by SELDI Mass Spectrometry. USA Patent No: 8198019, June 2012.
- Methods and Apparatus for Diagnosis and/or Prognosis of Cancers. USA Patent No: 8923598, Dec. 2014

Tatyana Zhukov

- **John Hopkins University (Research only)**
Location: Baltimore, MD | Date: 1991-1998
- **Moffitt Cancer Center (Research only)**
Location: Tampa, FL | Date: 1998-2011

Dansheng Song

- **Dept. of Radiology, College of Medicine, University of South Florida**
Location: Tampa, FL | Date: 1994-2005
- **Moffitt Cancer Center (Research only)**
Location: Tampa, FL | Date: 2005-2012

Victoria Link

- **Office of Advancement, Georgetown University**
Location: Washington, DC | Date: 1998-2019